The first reported case of metastatic CBT harboring a somatic-only SDHD variant with tumor-specific LOH is reported, suggesting that reliance on germline testing alone may underestimate the molecular drivers of CBT and highlights the potential clinical value of tumor-based genomic profiling for risk stratification and prognostic assessment.
Abstract
Carotid body tumors (CBTs) are rare paragangliomas in which genetic predisposition, particularly pathogenic variants in succinate dehydrogenase (SDHx) genes, plays an important role in tumorigenesis. Previous genetic studies of CBTs have primarily focused on germline SDHx variants, whereas somatic alterations remain poorly characterized. Among SDHx genes, SDHB variants are known to be associated with a higher metastatic risk, while SDHD variants are generally linked to a lower metastatic rate. We report the case of a 41-year-old man who presented with a painless right-sided neck mass. Imaging studies demonstrated a hypervascular tumor located at the carotid bifurcation with circumferential encasement of the carotid artery. During surgery, the tumor was classified as a Shamblin type III CBT, and complete surgical resection with vascular reconstruction was performed. Histopathological examination confirmed paraganglioma with metastasis to a single cervical lymph node. Germline genetic testing did not reveal any pathogenic variants. However, comprehensive tumor genomic profiling identified a somatic SDHD c.304C>G (p.His102Asp) variant accompanied by tumor-specific loss of heterozygosity (LOH) and copy-number loss at the SDHD locus, findings compatible with biallelic SDHD inactivation. The patient remained free of recurrence during follow-up. To our knowledge, this represents the first reported case of metastatic CBT harboring a somatic-only SDHD variant with tumor-specific LOH. This case suggests that reliance on germline testing alone may underestimate the molecular drivers of CBT and highlights the potential clinical value of tumor-based genomic profiling for risk stratification and prognostic assessment.
Background Very-early-onset colorectal cancer (CRC), particularly when clustered within a family, raises concern for an inherited cancer predisposition. However, the contribution of germline SDHB variants to CRC susceptibility remains uncertain. We report a family in which two sisters developed colorectal carcinoma bef...
Chang Liu, Da-Yang Zhou, Wen-Jing Xu et al.· Frontiers in Oncology· 0 citations
Background POLE-mutated endometrial carcinomas are associated with an excellent prognosis and have become an integral component of the molecular classification of endometrial carcinoma. However, the pathogenicity of many rare non-hotspot POLE exonuclease-domain variants remains uncertain, particularly when they occur i...
Yuxuan Yang, Hui-Mei Luo, Hui-Xing Yan et al.· Frontiers in Oncology· 0 citations
Background SMARCA4-deficient uterine sarcoma (SDUS) is a rare and aggressive undifferentiated uterine mesenchymal malignancy characterized by inactivation of SMARCA4 gene leading to loss of nuclear SMARCA4/BRG1 immunohistochemical staining. Fewer than 40 cases have been reported worldwide since its first description in...
Qun Liu, Hai-Li Kang, Jiao-Zhen Wang et al.· Frontiers in Oncology· 0 citations
DICER1 syndrome is a hereditary tumor predisposition syndrome caused by pathogenic germline variants in DICER1 and is characterized by multi-organ susceptibility; sarcomas remain uncommon within this spectrum. We report a 2-year-old girl with anaplastic sarcoma of the kidney (ASK). Molecular testing identified a germli...
M. Li, Guo-Qian He, Xia Guo et al.· Frontiers in Oncology· 0 citations
We report two maternally related women with ER-positive breast cancer carrying the germline BARD1 NM_000465.4:c.1519G>A (p.Val507Met) variant. This constitutional variant is currently classified as benign/likely benign and is not presented as causally related to the observed cancers. The study integrated longitudinal c...
Leylakhanim A. Melikova· Frontiers in Oncology· 0 citations
Introduction: Triple-negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. BRCA1 mutations occur in up to 20% of TNBC cases; simultaneous pathogenic variants in BRCA1 and PALB2 in a single patient are exceedingly rare, with poorly characterized combined clinical implications.
Case report: A 5...
Samuel Castro Campos, Sabas Carlos Vieira· Mastology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.